ACME UNITED CORP - 10-Q Summary (Period Ended June 30, 1998)
Business Context and Reporting Period
This Form 10-Q covers the quarterly and six-month periods ended June 30, 1998, for ACME UNITED CORPORATION, a Connecticut-based manufacturer of consumer and medical products. The company operates in the U.S., U.K., and international markets, with recent strategic shifts including the sale of certain wound care marketing rights to Seton Healthcare International Limited and the acquisition of the Rotex Division of Esselte Canada.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1998 | Six Months Ended June 30, 1997 |
|---|---|---|
| Net Sales | $23,763,000 | $23,734,000 |
| Net Income | $27,000 | $503,000 |
| Diluted EPS | $0.01 | $0.14 |
| Gross Profit Margin | 26.2% | 27.6% |
| Operating Cash Flow | ($1,456,000) used | ($4,328,000) used |
| Total Debt | $17,082,000 | $13,041,000 |
| Cash and Equivalents | $62,000 | $272,000 |
| Working Capital | $897,000 | $10,017,000 |
Material Changes vs. Prior Period
- Revenue Composition: While total net sales remained flat year-over-year, organic growth was positive. Excluding the impact of the Seton product line sale in 1997, sales increased 7% for the first half of 1998. Consumer products sales grew 10% in Q2, while medical sales declined 30% due to the Seton divestiture.
- Profitability: Net income dropped significantly to $27,000 from $503,000 in the prior year. The prior year included a one-time gain of $846,000 from the sale of marketing rights. Gross margins declined slightly, driven by the loss of high-margin Seton products and lower production volumes in the medical division.
- Liquidity and Debt: Working capital decreased sharply from $10.0 million to $0.9 million, and the current ratio fell from 1.86 to 1.04. Total debt increased by $4.0 million, primarily to fund the Rotex acquisition and support working capital needs. A significant portion of debt ($12.7 million) was reclassified from long-term to current due to a May 1999 maturity date.
- Cash Flow: Operating cash outflows improved significantly compared to the prior year, decreasing from $4.3 million used to $1.5 million used, aided by inventory management improvements.
Outlook, Risks, and Management Commentary
- Debt Maturity: Management is actively negotiating with lenders to extend the maturity date of $12.7 million in debt currently due in May 1999. They expect to complete this arrangement before December 1998.
- Future Revenue: The medical division secured a new contract with a national alternative care distributor expected to generate over $4 million in revenue over the next three years, with shipments starting in Q3 1998.
- Year 2000 Compliance: The company has implemented a new information system in the U.S. and established a task force. Management believes the Year 2000 issue will not materially affect financial results.
- Legal Proceedings: The company was released from the majority of lawsuits regarding latex products during the quarter. Remaining suits are in preliminary stages with no indication of product involvement; no significant financial impact is expected.
Investor Verification Checklist
- Debt Extension: Verify the status of negotiations to extend the $12.7 million debt maturity from May 1999.
- Liquidity Position: Monitor the current ratio (1.04) and working capital levels given the tight liquidity buffer.
- Medical Segment Recovery: Track the execution of the new $4 million distributor contract to offset the loss of Seton products.
- Organic Growth: Confirm sustained growth in the consumer product line (first aid, scissors) which drove the 10% Q2 increase.